Get it on Google Play

Cipla to Import Moderna’s COVID-19 Vaccine

Moderna’s Vaccine:

The Drugs Controller General of India (DCGI) has granted permission to Mumbai-based pharma major Cipla to import Moderna’s COVID-19 vaccine, making it the fourth vaccine in the country to be given the emergency use authorisation (EUA).

  • India has made available three COVID vaccines — Covaxin, Covishield and Sputnik.
  • The vaccine, mRNA-1273, manufactured by Moderna TX, Inc., is a two-dose vaccine with the shots to be given 28 days apart.
  • Messenger RNA vaccines, also called mRNA vaccines, are a new vaccine technology platform.
  • The mRNA vaccines teach human cells how to make a protein, or even just a piece of a protein of the virus, triggering an immune response inside human bodies.
  • The benefit of mRNA vaccines, like all vaccines, is that those vaccinated gain protection without ever having to risk the serious consequences of getting sick with Covid-19.
  • Vaccines and medicines, and even diagnostic tests and medical devices, require the approval of a regulatory authority before they can be administered.
  • In India, the regulatory authority is the Central Drugs Standard Control Organisation (CDSCO).
  • For vaccines and medicines, approval is granted after an assessment of their safety and effectiveness, based on data from trials.

Leave a Reply

Your email address will not be published. Required fields are marked *